• Home
  • About KinaseCentral

Kinase News

Entries RSS | Comments RSS
  • Blogroll

    • CrimsonCanary.com
    • KinaseCentral
    • PharmaCompanyPipelines
  • Tags

    AstraZeneca aurora Avastin bayer Bcr-Abl bevacizumab BMS c-kit cetuximab EGFR ErbB-2 ErbB2 erbitux Exelixis Genentech GlaxoSmithKline Gleevec GSK HER1 HER2 IGF-1R Imatinib ImClone JAK2 kinase Merck-Serono Met mTOR multikinase Nexavar Novartis onyx PDGF Pfizer phase I Phase II phase iii PI3K Preclinical regulatory Research Roche sorafenib VEGF VEGFR2
  • Providing a resource for information on kinase inhibitors

Bayer/Onyx initiate new Phase III trial for Nexavar in liver cancer

Posted on August 21, 2008 by crimsoncanary

Bayer and Onyx have announced the initiation of a Phase III study of Nexavar (sorafenib) as an adjuvant therapy for patients with hepatocellular carcinoma

Filed under: kinase | Tagged: bayer, kinase, multikinase, Nexavar, onyx, phase iii, sorafenib

« UCB describe series of PI3K inhibitors AstraZeneca partner with Singapore institutions for HCC »
  • Calendar

    • August 2008
      M T W T F S S
      « Jul   Sep »
       123
      45678910
      11121314151617
      18192021222324
      25262728293031
  • Blogroll

    • CrimsonCanary.com
    • KinaseCentral
    • PharmaCompanyPipelines

Blog at WordPress.com. Theme: Digg 3 Column by WP Designer